ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.9775
0.20%
Brent Oil
83.63
0.11%
Bitcoin
59,397.30
1.99%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. CRISPR Therapeutics AG (CRSP)

  7. CRISPR Therapeutics AG (CRSP) Noticias

CRSP CRISPR Therapeutics AG

55.19
1.38 (2.56%)
Fuera de horario
Última actualización: 16:41:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
CRISPR Therapeutics AG CRSP NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
1.38 2.56% 55.19 16:41:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
54.48 54.00 55.34 55.07 53.81
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/4/202415:30GLOBECRISPR Therapeutics to Present Oral Presentation at the..
03/4/202407:00GLOBECRISPR Therapeutics to Present at the Annual Needham Virtual..
01/4/202407:00GLOBECRISPR Therapeutics to Present at the American Society of..
13/3/202407:30GLOBECRISPR Therapeutics Proposes New Appointment to the Board of..
21/2/202416:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202416:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202406:50EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
21/2/202406:45EDGAR2Form 8-K - Current report
21/2/202406:30GLOBECRISPR Therapeutics Provides Business Update and Reports..
16/2/202416:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:30EDGAR2Form 144 - Report of proposed sale of securities
15/2/202407:30GLOBECRISPR Therapeutics to Present at the Citi 2024 Virtual..
13/2/202407:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202407:30GLOBECRISPR Therapeutics Announces $280 Million Registered Direct..
13/2/202405:30EDGAR2Form 8-K - Current report
13/2/202401:30GLOBEEuropean Commission Approves First CRISPR/Cas9 Gene-Edited..
31/1/202416:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202415:08EDGAR2Form 144 - Report of proposed sale of securities
29/1/202415:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202416:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202416:00EDGAR2Form 144 - Report of proposed sale of securities
16/1/202415:11EDGAR2Form 8-K - Current report
16/1/202415:01GLOBECRISPR Therapeutics Announces U.S. Food and Drug..
10/1/202410:36EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202406:00GLOBECRISPR Therapeutics Highlights Strategic Priorities and 2024..
03/1/202407:30GLOBECRISPR Therapeutics to Present at the 42nd Annual J.P...
19/12/202315:23EDGAR2Form 8-K - Current report
15/12/202307:58EDGAR2Form 8-K - Current report
13/12/202308:22EDGAR2Form 8-K - Current report
08/12/202315:11DJNBluebird Bio Shares Slide 41% on Black-Box Label, Higher..
08/12/202312:16EDGAR2Form 8-K - Current report
08/12/202311:52BWVertex and CRISPR Therapeutics Announce US FDA Approval of..
08/12/202310:46DJNCRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in..
04/12/202315:26EDGAR2Form 8-K - Current report
04/12/202315:15GLOBECRISPR Therapeutics Announces Updates to Immuno-Oncology..
16/11/202306:21EDGAR2Form 8-K - Current report
16/11/202300:45BW Vertex and CRISPR Therapeutics Announce Authorization of..
06/11/202315:42EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:33EDGAR2Form 8-K - Current report
06/11/202315:15GLOBECRISPR Therapeutics Provides Business Update and Reports..
06/11/202304:01GLOBECRISPR Therapeutics Announces Preclinical Data at the..
01/11/202305:29DJNCrispr Therapeutics Shares Rally Premarket After Favorable..
31/10/202316:53GLOBECRISPR Therapeutics Announces Completion of FDA Advisory..
31/10/202306:05GLOBECRISPR Therapeutics Trading Halted Today; FDA Advisory..
17/10/202316:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/10/202316:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/10/202316:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/10/202316:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202307:00GLOBECRISPR Therapeutics Proposes New Appointment to the Board of..
27/9/202308:01GLOBECRISPR Therapeutics to Present at the Society for..

Su Consulta Reciente

NASDAQ
CRSP
CRISPR Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados